| Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis J Wu, Z Huang, J Ren, Z Zhang, P He, Y Li, J Ma, W Chen, Y Zhang, ... Cell research 23 (8), 994-1006, 2013 | 509 | 2013 |
| RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome Y Zhang, SS Su, S Zhao, Z Yang, CQ Zhong, X Chen, Q Cai, ZH Yang, ... Nature communications 8 (1), 14329, 2017 | 503 | 2017 |
| RIP3 targets pyruvate dehydrogenase complex to increase aerobic respiration in TNF-induced necroptosis Z Yang, Y Wang, Y Zhang, X He, CQ Zhong, H Ni, X Chen, Y Liang, J Wu, ... Nature cell biology 20 (2), 186-197, 2018 | 235 | 2018 |
| Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy Y Wang, S Liu, Z Yang, AP Algazi, SH Lomeli, Y Wang, M Othus, A Hong, ... Cancer Cell 39 (10), 1375-1387. e6, 2021 | 98 | 2021 |
| 2-HG inhibits necroptosis by stimulating DNMT1-dependent hypermethylation of the RIP3 promoter Z Yang, B Jiang, Y Wang, H Ni, J Zhang, J Xia, M Shi, LM Hung, J Ruan, ... Cell reports 19 (9), 1846-1857, 2017 | 73 | 2017 |
| Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell ImmunityType II RAFi and MEKi to Treat MAPK … A Hong, M Piva, S Liu, W Hugo, SH Lomeli, V Zoete, CE Randolph, ... Cancer discovery 11 (3), 714-735, 2021 | 54 | 2021 |
| Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma P Dharanipragada, X Zhang, S Liu, SH Lomeli, A Hong, Y Wang, Z Yang, ... Cancer Discovery 13 (4), 880-909, 2023 | 38 | 2023 |
| Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma S Liu, HM Knochelmann, SH Lomeli, A Hong, M Richardson, Z Yang, ... Cell Reports Medicine 2 (10), 100411, 2021 | 30 | 2021 |
| Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Z Yang, Y Wang, S Liu, W Deng, SH Lomeli, G Moriceau, J Wohlschlegel, ... Cancer Discovery 12 (8), 1942-1959, 2022 | 27 | 2022 |
| Multi-organ landscape of therapy-resistant melanoma S Liu, P Dharanipragada, SH Lomeli, Y Wang, X Zhang, Z Yang, RJ Lim, ... Nature Medicine, 1-12, 2023 | 16 | 2023 |
| Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy K Manna, P Dharanipragada, D Alkam, NL Avaritt, CL Washam, ... bioRxiv, 2022.02. 15.480454, 2022 | | 2022 |
